Contact: Greg Mann Transcept Pharmaceuticals, Inc. Sr. Director, Corporate Communications (510) 215-3567 email@example.comSOURCE Transcept Pharmaceuticals, Inc.
Transcept Pharmaceuticals Announces That A Phase 2 Clinical Trial Of TO-2061 As Adjunctive Therapy For Obsessive Compulsive Disorder Did Not Meet Primary Endpoint
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.